化合物TG003 T1901
品牌 | 厂商性质 | 产地 | 货期 |
---|---|---|---|
TargetMol | 生产商 | 美国 | 现货 |
性能特点
生化试剂,可用于动物细胞实验
规格 | CAS号 | 价格 | 操作 |
---|---|---|---|
100 mg | 300801-52-9 | ¥5,230.00 | 询底价 |
10 mg | 300801-52-9 | ¥1,050.00 | 询底价 |
25 mg | 300801-52-9 | ¥1,980.00 | 询底价 |
5 mg | 300801-52-9 | ¥668.00 | 询底价 |
1 mL | 300801-52-9 | ¥693.00 | 询底价 |
2 mg | 300801-52-9 | ¥356.00 | 询底价 |
50 mg | 300801-52-9 | ¥3,630.00 | 询底价 |
1 mg | 300801-52-9 | ¥253.00 | 询底价 |
Product Introduction
Bioactivity
英文名: (E/Z)-TG003
描述: (E/Z)-TG003 是一种有效的 ATP 竞争性 Cdc2 样激酶 (Clk) 抑制剂,抑制 Clk1 和 Clk4 的 IC50值分别为 20 和 15 nM。它是 (Z)-TG003 和 (E)-TG003的消旋体。
细胞实验: 2 × 105 HeLa cells or 1.5 × 105 COS-7 cells resuspended in 2 mL of medium are plated on 6-well dishes, and 2 μL of 10 mM TG003 dissolved in Me2SO (final concentration at 10 μM), or 2 μL of Me2SO, is added to some wells. Cells are trypsinized, and the density is counted every 24 h for 3 days. Cells are then fixed with 1 mL of ice-cold 70% ethanol, washed with PBS, incubated in 1 ml of PBS containing 1 μg/mL DNase-free RNase A and 50 μg/mL propidium iodide for 20 min at 37 °C, and proceeded to cell cycle analysis by FACSCalibur.(Only for Reference)
激酶实验: In Vitro Kinase Assay : Kinase activity of Clks and SRPKs is assayed in a reaction mixture, containing 200 mM Tris-HCl (pH 7.5), 12.5 mM MgCl2, 8 mM dithiothreitol, 4 mM EGTA, 1–20 μM ATP, 1 μCi of [γ-32P]ATP, 1 μg of synthetic peptide of SF2/ASF RS domain (NH2-RSPSYGRSRSRSRSRSRSRSRSNSRSRSY-OH), and 0.1–1 μg of purified kinases in a final volume of 40 μL. cAMP-dependent protein kinase activity is assayed in a reaction mixture containing 80 mM Tris-HCl (pH 7.5), 12.5 mM MgCl2, 8 mM dithiothreitol, 4 mM EGTA, 10 μM ATP, 1 μCi of [γ-32P]ATP, 5 μg of histone H1, and 1 μg of catalytic subunit of rat cAMP-dependent protein kinase purified. Protein kinase C activity is assayed in a reaction mixture containing 200 mM Tris-HCl (pH 7.5), 12.5 mM MgCl2, 1 mM CaCl2, 80 μg/mL phosphatidylserine, 8 μg/mL diolein, 10 μM ATP, 1 μCi of [γ-32P]ATP, 5 μg of histone H1, and 2 μL of partially purified rat protein kinase C. The final concentration of Me2SO is adjusted to 1% regardless of inhibitor concentration. The reaction mixture is incubated at 30 or 25 °C for mammalian or Xenopus recombinant proteins, respectively, for 10 min, and a half-portion is spotted on P81 phosphocellulose membrane. The kinase assay conditions, including the incubation period and concentration of kinases and substrates, are optimized to maintain the linearity during incubation. The membrane is washed with 5% phosphoric acid solution (SF2/ASF RS domain) or 5% trichloroacetic solution (histone H1) at least over 15 min. The radioactivity is measured using a liquid scintillation counter. The net radioactivity is deduced by subtracting the background count from the reaction mixture without kinase, and the data are expressed as the percentage to the control sample containing the solvent.
体外活性: 10 μM TG003能够治疗非洲爪蟾体内过度Clk活性诱导的胚胎缺陷.
体内活性: TG003通过抑制IL-1β异核RNA的剪接阻断血小板产生IL-1β RNA。在3T3-L1脂肪细胞分化过程中,TG003也阻断PKCβII的可变剪接和PPARγ1和PPARγ2的表达。TG003通过抑制Clk1/Sty介导的磷酸化抑制人类β珠蛋白在体外的SF2/ASF依赖性剪接。TG003抑制哺乳动物细胞中Clk1/Sty激酶活性,而对10 μM浓度的HeLa和COS-7细胞的生长没有毒性作用。
存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
溶解度: DMSO : 6 mg/mL (24.06 mM)
Ethanol : < 1 mg/mL (insoluble or slightly soluble)
关键字: (E/Z) TG003 | Cyclin dependent kinase | (E/Z)-TG-003 | site | tumor | Wilm's | TG-003 | splice | inhibit | mutation | Inhibitor | TG 003 | CDK | (E/Z)-TG003 | cancer | (E/Z)TG003 | (E/Z)-TG 003 | breast
相关产品: S55746 | Wilfortrine | Triacetylresveratrol | Myricanol | A-385358 | 3',6-Disinapoylsucrose | Altholactone | AZD4320 | A-1331852 | Kobophenol A
相关库: Anti-Aging Compound Library | Anti-Breast Cancer Compound Library | Cell Cycle Compound Library | Bioactive Compounds Library Max | Inhibitor Library | Kinase Inhibitor Library | PPI Inhibitor Library | Apoptosis Compound Library | NO PAINS Compound Library | Bioactive Compound Library
化合物TG003 T1901信息由TargetMol中国为您提供,如您想了解更多关于化合物TG003 T1901报价、型号、参数等信息,欢迎来电或留言咨询。
注:该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案,不可用于临床诊断或治疗等相关用途